NCT05738720 Effect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD
| NCT ID | NCT05738720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saglik Bilimleri Universitesi |
| Condition | COPD Exacerbation |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2026-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2023-02-01 with a primary completion date of 2026-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is a randomized controlled trial. The cases will be divided into two groups as the Homespirometer group and the control group. Breathing exercises, aerobic exercise and peripheral muscle strengthening will be performed in both groups. A home-type spirometer will be given to the homespirometer group and it will be requested to send the spirometric measurement every week. The cases will be called to the hospital for control and evaluated at baseline, 3rd, 6th and 12th months. Evaluations include assessments such as exercise capacity measurement, muscle strength measurement, disease attack frequency, symptom scoring.
Eligibility Criteria
Inclusion Criteria: Being between the ages of 18-75 * Having a diagnosis of COPD stages C and D diagnosed according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) clinical diagnostic criteria * Presence of dyspnea on exertion * Stable clinical condition at the time of inclusion without infection or exacerbation in the previous 4 weeks * Having the ability to use a smart phone and spirometer after training Exclusion Criteria: * Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and needing high flow oxygen therapy (˃ 3-4 L \\min). * A history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training. * Participation in a pulmonary rehabilitation program within the past 12 months.
Contact & Investigator
Esra PEHLİVAN, Assoc. Prof.
PRINCIPAL INVESTIGATOR
Saglik Bilimleri Universitesi
Frequently Asked Questions
Who can join the NCT05738720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying COPD Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05738720 currently recruiting?
Yes, NCT05738720 is actively recruiting participants. Contact the research team at erdogan.cetinkaya@sbu.edu.tr for enrollment information.
Where is the NCT05738720 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT05738720 clinical trial?
NCT05738720 is sponsored by Saglik Bilimleri Universitesi. The principal investigator is Esra PEHLİVAN, Assoc. Prof. at Saglik Bilimleri Universitesi. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.